Search Details

Word: rheumatoid (lookup in dictionary) (lookup stats)
Dates: during 2000-2009
Sort By: most recent first (reverse)


Usage:

...biotechnology medicines in development last year for more than 100 diseases, half the new drugs approved in 2015 will be. Biologics average more than 20 times the cost of traditional drugs: treating breast cancer with a year's worth of the biologic Herceptin can cost $48,000; Remicade, for rheumatoid arthritis, can cost $20,000 annually. For other, rarer diseases, the price of biologic treatments can be as high as $200,000 a year...

Author: /time Magazine | Title: How Drug-Industry Lobbyists Won on Health-Care | 10/22/2009 | See Source »

...Harvard Medical School professor accused of plagiarizing a review of rheumatoid arthritis treatments turned in his resignation last week, over a year after the alleged infraction. The allegedly offending professor, Lee S. Simon, had his article in the biomedical journal “Best Practices & Research: Clinical Rheumatology” retracted last year. The retraction came after a data-comparison search engine found that about half the text of the article was taken verbatim from a paper published in 2003. Though he had not spoken directly with Simon about the matter, Simon M. Helfgott, a rheumatologist at Brigham and Women?...

Author: By Laura G. Mirviss, CRIMSON STAFF WRITER | Title: HMS Professor Simon Resigns | 3/13/2009 | See Source »

Hacohen’s research focuses on determining how immune responses are triggered under different conditions, including infections and for autoimmune reactions, such as organ transplant rejection or rheumatoid arthritis...

Author: By Alissa M D'gama, CRIMSON STAFF WRITER | Title: Harvard Gets $10M Donation | 2/3/2009 | See Source »

...million tiny glass plates most likely hold the future of Swiss pharmaceutical giant Roche. On each sits one of some 920,000 drug compounds Roche owns, which the researchers at its U.S. headquarters spend their day mixing and matching in the hope of finding the next cure for diabetes, rheumatoid arthritis or even cancer. Until now, however, 9 out of 10 times these searches have yielded only dead ends...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

...also grant older medications a new lease on life. Take the cancer drug MabThera, sold in the U.S. as Rituxan. MabThera was originally developed to treat non-Hodgkin's lymphoma. In 2006, Roche scientists noticed--again using biomarkers--that it was also extremely effective in certain cases of rheumatoid arthritis, a painful autoimmune condition that causes joint inflammation. Roche's sales to arthritis patients have already totaled more than $420 million...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next